Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Alberto Pérez-Rubio.
Revista Espanola De Salud Publica | 2008
Alberto Pérez-Rubio; J. Castrodeza Sanz; M. Gil Costa; F.J. Luquero Alcalde; J.M. Eiros Bouza; R. Ortiz de Lejarazu
Background: Chicken pox is a mainly childhood contagious disease caused by the Varicella Zoster Virus which gives rise to major healthcare and social costs. In 2005, Castile and Leon added chicken pox vaccine injections to its childhood vaccination schedule for eleven year-olds subject to coming down with this disease. This strategy does not modify the major mobility generated thereby at younger ages. This study is aimed at evaluating the profitability of systematic vaccination for chicken pox in infants 15 months of age in Castile and Leon. Methods: An economic cost-benefit evaluation has been set out by jeans of a decision-making tree. A fictitious cohort of 100,000 children in Castile and Leon having reached 15 months of age in 2004 is studied, to whom the chicken pox vaccine would be administered in conjunction with the mumps, measles, rubella vaccines. This study is approached from the social standpoint. The time horizon selected was that of up until the study cohort was to reach 15 years of age, applying a 3% discount rate. A sensitivity analysis was made for evaluating the uncertainty of some variables... Results: The cost-benefit ratio of adding this vaccine to the childhood vaccination schedule amounts to 1.23. Conclusions: From the social standpoint, administering chicken pox vaccine in conjunction with the mumps, measles, rubella vaccines show itself to be profitable. The profitability is modified both if a second dose of vaccine is added as well as if only the direct healthcare costs are analyzed.
Human Vaccines & Immunotherapeutics | 2018
Alberto Pérez-Rubio; José María Eiros Bouza
ABSTRACT The benefit of influenza vaccines is difficult to estimate due to the complexity of accurately assessing the burden of influenza. To improve the efficacy of influenza vaccines, vaccine manufacturers have developed quadrivalent influenza vaccine (QIV) formulations for seasonal vaccination by including both influenza B lineages. Three parallel approaches for producing influenza vaccines are attracting the interest of many vaccine manufacturing companies. The first and oldest is the conventional egg-derived influenza vaccine, which is used by the current licensed influenza vaccines. The second approach is a cell culture-derived influenza vaccine, and the third and most recent is synthetic vaccines. Here, we analyze the difficulties with vaccines production in eggs and compare this to cell culture-derived influenza vaccines and discuss the future of cell culture-derived QIVs.Keywords: Influenza vaccine, cell culture-derived, quadrivalent.
Revista Espanola De Salud Publica | 2010
Eva López-García; Socorro Fernández-Arribas; Alberto Pérez-Rubio; José María Eiros-Bouza; José Javier Castrodeza-Sanz
Fundamento: En abril del ano 2009 la Organizacion Mundial de la Salud declaro una Emergencia de Salud Publica de Importancia Internacional por la aparicion de casos en humanos por un nuevo virus de la gripe A H1N1. El objetivo de este trabajo es analizar las caracteristicas de los casos investigados y valorar la conformidad de los sujetos estudiados con las indicaciones y recomendaciones de la Consejeria de Sanidad de Castilla y Leon. Metodos: Estudio epidemiologico descriptivo del total de las peticiones de laboratorio solicitadas en Castilla y Leon, entre las semanas epidemiologicas 44 y 50, ambas inclusive y de los casos que resultaron positivos. Resultados: Se solicitaron 588 peticiones analiticas para gripe A H1N1 (58% hombres). La edad media fue de 34,8 anos (27,1% entre 15 y 44 anos) y la enfermedad respiratoria cronica el factor de riesgo mas frecuente (18,9%). En el 19,1% se instauro tratamiento antiviral (54,5% en las primeras 48 horas). El 42% de las peticiones cumplian criterios de gravedad y el 27,4% de las peticiones fueron positivas (53,4% varones). La edad media en las peticiones positivas fue 34,52 anos (33,1% entre 15 y 44 anos). En el 26,7% el factor de riesgo mas frecuente fue la enfermedad respiratoria cronica, el 6,8% tenia obesidad morbida. El 28,9% de los sujetos que dieron positivo recibio tratamiento antiviral (61,4% en las primeras 48 horas) y el 47,8% cumplian criterios de gravedad. Conclusion: La mayoria de los casos estudiados no cumplian criterios de gravedad, lo que pone de manifiesto el bajo cumplimiento de los protocolos de vigilancia en el ambito asistencial.
Medicina Clinica | 2010
Alberto Pérez-Rubio; José María Eiros Bouza; José Sanz
Revista Portuguesa De Pneumologia | 2014
Alberto Pérez-Rubio; José María Eiros Bouza
Atencion Primaria | 2015
José María Eiros Bouza; Alberto Pérez-Rubio
Revista médica del Instituto Mexicano del Seguro Social | 2017
Miguel López-Gobernado; Alberto Pérez-Rubio; Eva López-García; Agustín Mayo-Iscar; José María Eiros
Trials in Vaccinology | 2016
Alberto Pérez-Rubio; Francisco J. Luquero; María Rosario Bachiller Luque; Paz de la Torre Pardo; José María Eiros Bouza
Revista Portuguesa De Pneumologia | 2014
Alberto Pérez-Rubio; Socorro Fernández Arribas; José María Eiros Bouza
Gaceta Sanitaria | 2014
Alberto Pérez-Rubio; Socorro Fernández Arribas; José María Eiros Bouza